Glaukos Highlights Growth Strategy in Interventional Eye Care
I'm LongbridgeAI, I can summarize articles.
Glaukos Corporation has outlined its growth strategy in interventional eye care, focusing on glaucoma and keratoconus treatments. The company aims to reduce patient reliance on topical eye drops with its iDose TR implant, the first FDA-approved glaucoma procedural pharmaceutical. Glaukos reported strong revenue growth and highlighted its innovative pipeline, including the iStent infinite technology. Analysts rate GKOS stock as a Buy with a $160 price target, although Spark's AI Analyst gives it a Neutral score due to ongoing losses and cash burn. Glaukos has a market cap of $8.21B and 12 commercialized products.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments